Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

MAP4K4-IN-3

Copy Product Info
😃Good
Catalog No. T11942Cas No. 1811510-58-3
Alias Compound 17

MAP4K4-IN-3 (Compound 17), a serine/threonine protein kinase, may be a viable target for antidiabetic agents.

MAP4K4-IN-3

MAP4K4-IN-3

Copy Product Info
😃Good
Purity: 98.07%
Catalog No. T11942Alias Compound 17Cas No. 1811510-58-3
MAP4K4-IN-3 (Compound 17), a serine/threonine protein kinase, may be a viable target for antidiabetic agents.
Pack SizePriceUSA WarehouseGlobal WarehouseQuantity
5 mg$39In StockIn Stock
10 mg$72In StockIn Stock
25 mg$155In StockIn Stock
50 mg$247In StockIn Stock
100 mg$393In StockIn Stock
200 mg$582-In Stock
500 mg$885-In Stock
1 mL x 10 mM (in DMSO)$43In StockIn Stock
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Questions
TargetMol
View More

Batch Information

Select Batch
Purity:98.07%
Appearance:Solid
Color:White
Contact us for more batch information

Resource Download

Product Introduction

Bioactivity
Description
MAP4K4-IN-3 (Compound 17), a serine/threonine protein kinase, may be a viable target for antidiabetic agents.
Targets&IC50
MAP4K4:14.9 nM
In vitro
MAP4K4-IN-3, Antidiabetic agent.MAP4K4-IN-3 is a potent and selective MAP4K4 inhibitor with an IC50 of 14.9 nM in kinase assay, an IC50 of 470 nM in cell assay.
In vivo
Administering MAP4K4-IN-3 (Compound 2; 25 mg/kg, b.i.d.) orally to telemetered rats over a period of five days induces several adverse reactions. Cardiovascular measurements reveal a significant increase in maximal heart rate by 25 beats per minute (bpm) compared to control groups upon treatment with MAP4K4-IN-3[2]. Additionally, there are noticeable declines in body weight (7%) and an increase in body temperature (0.4°C) against control values throughout the study.
SynonymsCompound 17
Chemical Properties
Molecular Weight297.74
FormulaC15H12ClN5
Cas No.1811510-58-3
SmilesNc1ncc(cn1)-c1cnc(N)c(c1)-c1ccc(Cl)cc1
Relative Density.1.377 g/cm3 (Predicted)
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
Solubility Information
DMSO: 8 mg/mL (26.87 mM), Sonication is recommended.
Solution Preparation Table
DMSO
1mg5mg10mg50mg
1 mM3.3586 mL16.7932 mL33.5864 mL167.9318 mL
5 mM0.6717 mL3.3586 mL6.7173 mL33.5864 mL
10 mM0.3359 mL1.6793 mL3.3586 mL16.7932 mL
20 mM0.1679 mL0.8397 mL1.6793 mL8.3966 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
TargetMol | Animal experiments For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent 10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.
Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSOTargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSOTargetMol | reagent stock solution to 400 μL PEG300TargetMol | reagent and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH2OTargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy MAP4K4-IN-3 | purchase MAP4K4-IN-3 | MAP4K4-IN-3 cost | order MAP4K4-IN-3 | MAP4K4-IN-3 chemical structure | MAP4K4-IN-3 in vivo | MAP4K4-IN-3 in vitro | MAP4K4-IN-3 formula | MAP4K4-IN-3 molecular weight